Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia 12Leukemia, Myeloid, Acute 9Leukemia, Myelomonocytic, Acute 7Leukemia, Monocytic, Acute 7Leukemia, Megakaryoblastic, Acute 7Leukemia, Erythroblastic, Acute 7Congenital Abnormalities 6Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Myelodysplastic Syndromes 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Radiotherapy 3Methotrexate 3Cytarabine 3Cyclosporine 3Peripheral Blood Stem Cell Transplantation 2Daunorubicin 2Cyclophosphamide 2Busulfan 2zosuquidar trihydrochloride 1sargramostim 1merphos 1hydrocortisone hemisuccinate 1Whole-Body Irradiation 1Thioguanine 1Stem Cell Transplantation 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methoxsalen 1Idarubicin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Cyclosporins 1Colony-Stimulating Factors 1Asparaginase 1Antilymphocyte Serum 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Anemia, Refractory, with Excess of Blasts × Gemtuzumab × Clear all
NCT00077116 2012-07-16

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
31 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡